Skip to main content
. 2011 Jul 18;121(8):3100–3108. doi: 10.1172/JCI43656

Figure 7. Tumor STAT6 dictates clinical response to platinum-based therapy in cancer patients.

Figure 7

(A) STAT6 expression by squamous cell carcinoma of the head and neck. (B) STAT6-negative tumor with immune infiltrates as internal positive control. Original magnification, ×250. (C) Kaplan-Meier estimates of recurrence-free survival of patients with (n = 35) or without (n = 21) tumor STAT6 expression (P = 0.038). The time to recurrence was analyzed in a cohort of head and neck cancer patients that had been treated with cisplatin and radiotherapy in our institute in the period of 2003–2007. (D) Kaplan-Meier estimates of recurrence-free survival of patients with (n = 24) or without (n = 24) tumor STAT6 expression (P = 0.065). The time to recurrence was analyzed in a cohort of head and neck cancer patients that had been treated with radiotherapy alone in our institute in the period of 2000–2009.